Nature of Disclosure: Regulatory filing pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, regarding board meeting outcomes.

Board Meeting Details: The Board of Directors meeting was held on October 12, 2026, commencing at 11:00 A.M. and concluding at 12:15 P.M.

Key Approval 1 - NCD Issuance: The Board approved the issuance of up to 80,000 fully paid-up, rupee denominated, secured/unsecured, listed, rated, redeemable and transferable non-convertible debentures of face value ₹1,00,000 each. The total issue size aggregates up to ₹800 crore (₹800,00,00,000) to be issued on a private placement basis in one or more tranches, subject to applicable laws and regulatory approvals.

Key Approval 2 - Shareholder Authorization: The Board approved seeking member authorization through a Special Resolution via Postal Ballot for issuance of non-convertible debt securities on private placement basis. The authorization seeks approval for an aggregate amount not exceeding ₹2,500 crore outstanding at any point of time during a period of one year from the date of passing the Special Resolution.

Instrument Details:

  • Type: Non-Convertible Debentures (secured/unsecured, rated, listed, redeemable)
  • Issue Method: Private Placement
  • Face Value: ₹1,00,000 per NCD
  • Listing: Proposed to be listed on Bombay Stock Exchange Limited (BSE)
  • Tenure: Up to five years from the Deemed Date of Allotment
  • Coupon/Interest: To be discovered during bidding process
  • Payment Frequency: Annually, monthly or early redemption date as applicable
  • Security: As prescribed in Key Information Document (KID)
  • Special Rights: As specified in relevant Information Memorandum/Key Terms

Regulatory References: Filed under Regulation 30 read with Schedule III of SEBI Listing Regulations and SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Additional Information: The documents will be available on the company's website at www.jubilantpharmova.com. The disclosure was signed by Naresh Kapoor, Company Secretary.

Financial Impact: The issuance could raise up to ₹800 crore in immediate funding with authorization for additional debt raising up to ₹2,500 crore outstanding limit over one year.